Blood Clot Concerns Prompt EU Restrictions For Pfizer's Xeljanz

The European Medicines Agency's pharmacovigilance committee has launched a fresh review of Xeljanz and has also recommended suspending all fenspiride medicines, which are used to treat non-serious cough but are associated with heart rhythm problems.

SideEffects
The EMA Is Re-Examining The Safety Of Xeljanz • Source: Shutterstock

More from Europe

More from Geography